{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:51:14Z","timestamp":1791366674391,"version":"4.3.1"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>These post hoc analyses of 2 phase 3 myelofibrosis trials assessed the kinetics and prognostic value of achieving hemoglobin \u2265\u200910\u2009g\/dL with momelotinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Median (range) time to hemoglobin \u2265\u200910\u2009g\/dL was assessed in momelotinib\u2010randomized patients with baseline hemoglobin &lt;\u200910\u2009g\/dL in the SIMPLIFY\u20101 (JAK inhibitor naive) and MOMENTUM (JAK inhibitor experienced) trials. Survival from treatment initiation was evaluated via Kaplan\u2013Meier curves and Cox models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In SIMPLIFY\u20101, 54\/86 patients (63%) achieved hemoglobin \u2265\u200910\u2009g\/dL by week 24: moderate anemia, 40\/58 (69%), 0.6 (0.4\u20135.1) months; severe anemia, 14\/28 (50%), 1.4 (0.5\u20134.7) months. In MOMENTUM, 45\/126 patients (36%) achieved hemoglobin \u2265\u200910\u2009g\/dL by week 24: moderate anemia, 30\/64 (47%), 0.5 (0.3\u20134.6) months; severe anemia, 15\/62 (24%), 0.5 (0.5\u20135.6) months. Achieving hemoglobin \u2265\u200910\u2009g\/dL by week 24 was numerically associated with longer survival: SIMPLIFY\u20101 HR, 0.53 (95% CI, 0.27\u20131.05); MOMENTUM HR, 0.62 (95% CI, 0.33\u20131.15). In multivariate analysis, only week 24 transfusion independence was associated with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Achievement of hemoglobin \u2265\u200910\u2009g\/dL may be a clinically meaningful target in momelotinib\u2010treated patients with myelofibrosis and anemia. Those without JAK inhibitor experience and\/or with moderate anemia were more likely and faster to achieve this threshold, supporting earlier momelotinib initiation to optimize outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:bold>Trial Registration:<\/jats:bold>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      identifier: NCT01969838, NCT04173494\n                    <\/jats:title>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70237","type":"journal-article","created":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T04:51:50Z","timestamp":1784091110000},"page":"1265-1274","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of Hemoglobin Improvement on Survival in Patients With Myelofibrosis and Anemia Treated With Momelotinib in the\n                    <scp>SIMPLIFY<\/scp>\n                    \u20101 and\n                    <scp>MOMENTUM<\/scp>\n                    Trials"],"prefix":"10.1111","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8367-5668","authenticated-orcid":false,"given":"Francesca","family":"Palandri","sequence":"first","affiliation":[{"name":"IRCCS Azienda Ospedaliero\u2010Universitaria di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-3911","authenticated-orcid":false,"given":"Casey","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Keck School of Medicine of the University of Southern California  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9779-6217","authenticated-orcid":false,"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"The University of Alabama at Birmingham  Birmingham Alabama USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1224-091X","authenticated-orcid":false,"given":"Donal P.","family":"McLornan","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Koschmieder","sequence":"additional","affiliation":[{"name":"RWTH Aachen University and Center for Integrated Oncology Aachen Bonn Cologne D\u00fcsseldorf (CIO ABCD)  Aachen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4289-3113","authenticated-orcid":false,"given":"Juan Carlos","family":"Hernandez\u2010Boluda","sequence":"additional","affiliation":[{"name":"Hospital Cl\u00ednico Universitario de Valencia\u2010INCLIVA, University of Medicine  Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Shimoda","sequence":"additional","affiliation":[{"name":"University of Miyazaki  Miyazaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ellis","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Lim","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Sahni","sequence":"additional","affiliation":[{"name":"GSK  Collegeville Pennsylvania USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1419-8607","authenticated-orcid":false,"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"The Princess Margaret Cancer Centre  Toronto Ontario Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0028-x"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71729"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.2446"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-245837"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-170449"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234064"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000778"},{"key":"e_1_2_11_9_1","unstructured":"\u201cNCCN Clinical Practice Guidelines in Oncology Myeloproliferative Neoplasms \u201dV1.2026."},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1845334"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34722"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.031831"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-575373"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv203"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2328800"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2011.11.001"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)02036-0"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010151"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.5818"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740092"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002662"},{"key":"e_1_2_11_22_1","unstructured":"Omjjara (momelotinib) \u201cSummary of Product Characteristics \u201dGSK 2024 accessed March 6 2026 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/omjjara\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_11_23_1","unstructured":"Ojjaara (momelotinib) \u201cPrescribing Information \u201dGSK 2023 accessed March 6 2026 https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Ojjaara\/pdf\/OJJAARA\u2010PI\u2010PIL.PDF."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00174-6"},{"key":"e_1_2_11_25_1","doi-asserted-by":"crossref","unstructured":"S.Verstovsek S. T.Oh J.\u2010J.Kiladjian et\u00a0al. \u201cTransfusion Independence Response as a Potential Surrogate for Overall Survival in JAKi\u2010Experienced Patients With Myelofibrosis From MOMENTUM \u201dASH 2022 Poster 3028.","DOI":"10.1182\/blood-2022-162877"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01637-7"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.4418"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2043304"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.10.001"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05229.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06142.x"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2435-7"},{"key":"e_1_2_11_33_1","doi-asserted-by":"crossref","unstructured":"S.Oh R.Mesa C. N.Harrison et\u00a0al. \u201cPacritinib Is a Potent ACVR1 Inhibitor With Significant Anemia Benefit in Patients With Myelofibrosis \u201dASH 2022 Oral Presentation 628.","DOI":"10.1182\/blood-2022-156936"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025802"},{"key":"e_1_2_11_35_1","doi-asserted-by":"crossref","unstructured":"P.Vachhani J.Repp J. E.Hamer\u2010Maansson et\u00a0al. \u201cClinical Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib and Anemia\u2010Supporting Medications \u201dEHA 2025 Oral Presentation S218.","DOI":"10.1016\/S2152-2650(25)00913-9"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02928-4"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2550924"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151449"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70320"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0964"},{"key":"e_1_2_11_41_1","doi-asserted-by":"crossref","unstructured":"L.Fletcher N.Niehoff S.Sura et\u00a0al. \u201cReal\u2010World Baseline Characteristics and Preliminary Outcomes in Patients With Myelofibrosis Treated With Momelotinib in the US Community Oncology Practice Setting \u201dASH 2024 Poster 2430.","DOI":"10.1182\/blood-2024-199834"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70237","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ejh.70237","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70237","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T09:03:49Z","timestamp":1791363829000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1111\/ejh.70237"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70237","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"2026-04-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}